Related references
Note: Only part of the references are listed.Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial
P. Gardner-Sood et al.
PSYCHOLOGICAL MEDICINE (2015)
Cardiovascular Risk Prediction Models for People With Severe Mental Illness Results From the Prediction and Management of Cardiovascular Risk in People With Severe Mental Illnesses (PRIMROSE) Research Program
David P. J. Osborn et al.
JAMA PSYCHIATRY (2015)
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
MARC DE HERT et al.
World Psychiatry (2015)
Standard cardiovascular disease risk algorithms underestimate the risk of cardiovascular disease in schizophrenia: Evidence from a national primary care database
Gary McLean et al.
SCHIZOPHRENIA RESEARCH (2014)
PRIMARY CARE Statins for primary prevention of cardiovascular disease
Azeem Majeed
BMJ-BRITISH MEDICAL JOURNAL (2014)
Comorbidities and Mortality in Persons With Schizophrenia: A Swedish National Cohort Study
Casey Crump et al.
AMERICAN JOURNAL OF PSYCHIATRY (2013)
The prevalence of metabolic syndrome amongst patients with severe mental illness in the community in Hong Kong - a cross sectional study
Daniel T. Bressington et al.
BMC PSYCHIATRY (2013)
A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness
Gail L. Daumit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Screening for Metabolic Risk Among Patients With Severe Mental Illness and Diabetes: A National Comparison
Alex J. Mitchell et al.
PSYCHIATRIC SERVICES (2013)
Is the Prevalence of Metabolic Syndrome and Metabolic Abnormalities Increased in Early Schizophrenia? A Comparative Meta-Analysis of First Episode, Untreated and Treated Patients
Alex J. Mitchell et al.
SCHIZOPHRENIA BULLETIN (2013)
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants
Goodarz Danaei et al.
LANCET (2011)
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
Marc De Hert et al.
WORLD PSYCHIATRY (2011)
The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness
R. I. G. Holt et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Cardiovascular Abnormalities in Patients with Major Depressive Disorder Autonomic Mechanisms and Implications for Treatment
Alex D. H. Brown et al.
CNS DRUGS (2009)
Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes
Elaine H. Morrato et al.
DIABETES CARE (2009)
Obesity, serious mental illness and antipsychotic drugs
Richard I. G. Holt et al.
DIABETES OBESITY & METABOLISM (2009)
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)
M. De Hert et al.
EUROPEAN PSYCHIATRY (2009)
Creating medical and drug code lists to identify cases in primary care databases
Shreya Dave et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean?
David B. Allison et al.
PSYCHIATRY RESEARCH (2009)
Common mental disorder and obesity-insight from four repeat measures over 19 years: prospective Whitehall II cohort study
Mika Kivimaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics
Christoph U. Correll et al.
BIPOLAR DISORDERS (2008)
First- V. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis
M. Smith et al.
BRITISH JOURNAL OF PSYCHIATRY (2008)
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
Gail L. Daumit et al.
SCHIZOPHRENIA RESEARCH (2008)
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
A. H. Barnett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2007)
Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database
David P. J. Osborn et al.
ARCHIVES OF GENERAL PSYCHIATRY (2007)
Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry
Dan Cohen et al.
CNS DRUGS (2007)
Dietary improvement in people with schizophrenia - Randomised controlled trial
RG McCreadie et al.
BRITISH JOURNAL OF PSYCHIATRY (2005)
Consensus development conference on antipsychotic drugs and obesity and diabetes
DIABETES CARE (2004)
Physical health monitoring of patients with schizophrenia
SR Marder et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)